CVS rises after beating Wall Street estimates
CVS Health rose more than 8% in premarket trading after it reported earnings that beat Wall Street estimates and raised its full-year guidance.
The company posted earnings per share of $2.25, more than the $1.70 analysts polled by FactSet were expecting. It also reported $94.5 billion in revenue, higher than the $93.6 billion analysts estimated. The company now expects full-year earnings of $6 to $6.20 per share, up from $5.75 to $6 per share.
CVS’s insurance arm, Aetna, said that in 2026 it will withdraw from the Affordable Care Act exchange business, which is losing money. It also announced that its pharmacy benefit manager, CVS Caremark, partnered with Novo Nordisk to “increase access” to Wegovy, the blockbuster weight-loss drug.